E Fund Management Co. Ltd. Has $355,000 Stock Position in Insulet Co. (NASDAQ:PODD)

E Fund Management Co. Ltd. increased its position in shares of Insulet Co. (NASDAQ:PODD) by 53.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,359 shares of the medical instruments supplier’s stock after buying an additional 471 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Insulet were worth $355,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Baillie Gifford & Co. raised its stake in Insulet by 3.5% during the 4th quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier’s stock worth $614,998,000 after buying an additional 79,982 shares during the period. Geode Capital Management LLC raised its stake in Insulet by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock worth $403,339,000 after buying an additional 22,850 shares during the period. Westfield Capital Management Co. LP raised its stake in Insulet by 27.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after buying an additional 163,388 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Insulet by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 646,959 shares of the medical instruments supplier’s stock worth $168,902,000 after buying an additional 10,694 shares during the period. Finally, Fisher Asset Management LLC raised its stake in Insulet by 7.6% during the 4th quarter. Fisher Asset Management LLC now owns 377,694 shares of the medical instruments supplier’s stock worth $98,605,000 after buying an additional 26,594 shares during the period.

Insider Buying and Selling at Insulet

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Lauren Budden sold 915 shares of the stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is owned by corporate insiders.

Insulet Stock Performance

PODD stock opened at $251.81 on Friday. The firm has a market cap of $17.68 billion, a PE ratio of 43.49, a P/E/G ratio of 3.62 and a beta of 1.29. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The business has a 50 day moving average of $274.09 and a 200-day moving average of $252.86. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $289.46.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The company had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. As a group, sell-side analysts expect that Insulet Co. will post 3.92 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on PODD shares. Piper Sandler upped their price target on Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Canaccord Genuity Group increased their price objective on Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Morgan Stanley increased their price objective on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. JPMorgan Chase & Co. increased their price objective on Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research note on Thursday, December 12th. Finally, Royal Bank of Canada assumed coverage on Insulet in a research note on Thursday. They issued an “outperform” rating and a $340.00 price objective for the company. Four investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $292.06.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.